Compare PLX & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PLX | VBF |
|---|---|---|
| Founded | 1993 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 182.9M | 169.8M |
| IPO Year | 1996 | 1995 |
| Metric | PLX | VBF |
|---|---|---|
| Price | $2.72 | $14.18 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 672.2K | 83.9K |
| Earning Date | 05-12-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $52,744,000.00 | N/A |
| Revenue This Year | $36.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.19 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.60 | $14.18 |
| 52 Week High | $3.19 | $15.86 |
| Indicator | PLX | VBF |
|---|---|---|
| Relative Strength Index (RSI) | 55.19 | 24.34 |
| Support Level | $2.59 | N/A |
| Resistance Level | $2.75 | $15.21 |
| Average True Range (ATR) | 0.09 | 0.17 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 42.87 | 10.34 |
Protalix BioTherapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, production, and commercialization of therapeutics for rare diseases with important unmet needs. ProCellEx, a proprietary plant cell-based protein expression system, represents a new method for developing recombinant proteins in an industrial-scale manner. corporate includes the development of treatments for rare and orphan diseases. The Company operates as a single operating segment in Israel.
Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.